<p>The goal of this study was to determine how patients with T-ALL who have DNA methyltransferase 3 alpha (<a href="https://www.ncbi.nlm.nih.gov/gene/1788">DNMT3A</a>) mutations develop resistance to therapy. Since DNMT3A is a methyltransferase, we examined the effect of those mutations on epigenetic regulation using whole genome bisulfite sequencing (WGBS). We also assessed any changes in gene expression using RNA-sequencing. We found that T-ALL patients with DNMT3A mutations are resistant to apoptosis and some chemotherapies. WGBS showed that DNMT3A mutated patients clustered together by their epigenetic profile, which was associated with hypomethylation at <a href="https://www.ncbi.nlm.nih.gov/gene/7015">TERT </a>and HOX genes. RNA sequencing identified differences in JAK/STAT signaling. </p>

BIRC5 Upregulation Enhances DNMT3A-Mutant T-ALL Cell Survival and    Pathogenesis

Leukemia-Lymphoma, Adult T-Cell study with Bisulfite-Seq, RNA-Seq data on dbGaP (10 participants)

BIRC5 Upregulation Enhances DNMT3A-Mutant T-ALL Cell Survival and Pathogenesis

Description

Applying For Access

Summary